Dry eye syndrome, meibomian gland dysfunction Eye Diseases
Conditions
Interventions
Patients are randomized using the random number method into two treatment groups.
The first group will use 0.15% sodium hyaluronate ophthalmic solution (Hyalu Mini®, Hanmi P harma Inc., Seoul, Korea)
Sponsors
Pusan National University Yangsan Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Be male or female, aged 19 years to 90 years 2. Have a tear breakup time (TBUT) of 10 seconds or more 3. Have a Schirmer’s I test result of 10 mm or more 4. Have not used diquafosol-based eye drops, artificial tear drops, steroid eye drops, or antibiotic eye drops within 3 months before participation 5. Show normal blinking during a slit lamp exam 6. Voluntarily agree to participate in this study
Exclusion criteria
Exclusion criteria: 1. Has Sjögren's syndrome 2. Has severe blepharitis 3. Had ocular surgery or laser eye surgery 4. Has severe ocular inflammation/infection 5. Is using eye drop treatment for dry eyes, such as glaucoma or allergies 6. Shows sensitivity to the study drugs 7. Is considered to be ineligible for participation owing to reasons other than the aforementioned exclusion criteria based on the judgment of the principal researcher
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Measured at baseline (1 week before cataract surgery) and 1, 3, 6 weeks after cataract surgery: 1. Ocular surface status parameters: 1.1. Lipid layer thickness (LLT) measured using an interferometer 1.2. Schirmer’s type I test using COLOR BAR by Eagle Vision Inc. 1.3. Tear breakup time (TBUT), corneal staining score(CSS), meiboscore were measured by an ophthalmologist 2. Patients’ symptoms measured using Ocular Surface Disease Index (OSDI) questionnaire | — |
Secondary
| Measure | Time frame |
|---|---|
| There are no secondary outcome measures | — |
Countries
Korea, South
Outcome results
None listed